Chinese Journal of Cancer Research

Papers
(The H4-Index of Chinese Journal of Cancer Research is 16. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-05-01 to 2026-05-01.)
ArticleCitations
Efficacy of ctDNA methylation combined with traditional detection modality to detect liver cancer among high-risk patients: A multicenter diagnostic trial97
Pathogenic germline variants in mismatch repair genes in patients with microsatellite instability-high gastric cancer72
Focal ablation therapy presents promising results for selectively localized prostate cancer patients67
Gastric cancer surgery in South Korea: Past, present, and future44
Molecular features of gastroenteropancreatic neuroendocrine carcinoma: A comparative analysis with lung neuroendocrine carcinoma and digestive adenocarcinomas36
Efficacy and safety of low-dose cyclophosphamide combined with lenvatinib, pembrolizumab and TACE for unresectable hepatocellular carcinoma: A single-center, prospective, single-arm clinical trial35
Transforming cancer cells for long-term living with cancer: An inspiring new approach32
Plasma cell-free DNA methylation markers for detection and prognosis of gastric cancer: A case-control study31
Gut microbiota and acute graft-versus-host disease26
Clinical and molecular significance of homologous recombination deficiency positive non-small cell lung cancer in Chinese population: An integrated genomic and transcriptional analysis23
Detection and classification of breast lesions using multiple information on contrast-enhanced mammography by a multiprocess deep-learning system: A multicenter study20
Microbiota and urinary tumor immunity: Mechanisms, therapeutic implications, and future perspectives19
Tislelizumab in previously treated, locally advanced unresectable/metastatic microsatellite instability-high/mismatch repair-deficient solid tumors19
Mn-based cGAS-STING activation for tumor therapy19
Impact of resection margin status on survival in gastric cancer: A retrospective cohort study17
Updates of CSCO guidelines for colorectal cancer version 202517
Sequential neoadjuvant chemotherapy using pegylated liposomal doxorubicin and cyclophosphamide followed by taxanes with complete trastuzumab and pertuzumab treatment for HER2-positive breast cancer: A16
Prophylactic hyperthermic intraperitoneal chemotherapy in patients with locally advanced gastric cancer after curative surgery: Final results of a phase II trial16
0.21501803398132